Daisy Genomics and New Day Diagnostics have announced a research collaboration that brings together two very different bets on early cancer detection: liquid biopsy and physics-based sequencing. The goal isn’t just better data — it’s removing long-standing bottlenecks that have limited how early, scalable, and affordable CRC screening can truly be.
At the center of the effort is direct detection of epigenetic signals, including tumor-specific DNA methylation markers, without relying on traditional chemical amplification or sequencing workflows. If successful, this approach could reshape assumptions about what’s required to detect colorectal cancer at its earliest, most treatable stages.
What makes this collaboration notable is where it’s happening and how it’s structured — spanning a CLIA-certified lab, an academic research ecosystem, and advanced manufacturing capabilities. Together, they’re positioning Tennessee as a testbed for next-generation cancer diagnostics rather than just another validation site.